公开(公告)号：WO2014100071A2

公开(公告)日：2014-06-26

申请号：PCT/US2013075917

申请日：2013-12-18

Applicant: MERCK SHARP & DOHME ,  DINSMORE CHRISTOPHER ,  FRADERA LLINAS FRANCESC XAVIER ,  KUDALE AMIT ASHOKRAO ,  MACHACEK MICHELLE ,  REUTERSHAN MICHAEL HALE ,  THOMPSON CHRISTOPHER FRANCIS ,  TROTTER B WESLEY ,  YANG LIPING ,  ALTMAN MICHAEL D ,  BOGEN STEPHANE L ,  DOLL RONALD J ,  VOSS MATTHEW E

Inventor： DINSMORE CHRISTOPHER ,  FRADERA LLINAS FRANCESC XAVIER ,  KUDALE AMIT ASHOKRAO ,  REUTERSHAN MICHAEL HALE ,  THOMPSON CHRISTOPHER FRANCIS ,  YANG LIPING ,  ALTMAN MICHAEL D ,  BOGEN STEPHANE L ,  DOLL RONALD J ,  VOSS MATTHEW E

IPC: C07D487/04 ,  A61K31/519

CPC classification number: C07D487/04

Abstract: The present invention provides substituted pyrrolopyrimidines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract translation: 本发明提供如本文所述的取代吡咯并嘧啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。

公开(公告)号：WO2014100071A3

公开(公告)日：2014-06-26

申请号：PCT/US2013/075917

申请日：2013-12-18

Applicant: MERCK SHARP & DOHME CORP. ,  DINSMORE, Christopher ,  FRADERA LLINAS, Francesc Xavier ,  KUDALE, Amit Ashokrao ,  MACHACEK, Michelle ,  REUTERSHAN, Michael Hale ,  THOMPSON, Christopher Francis ,  TROTTER, B. Wesley ,  YANG, Liping ,  ALTMAN, Michael, D. ,  BOGEN, Stephane, L. ,  DOLL, Ronald, J. ,  VOSS, Matthew, E.

Inventor： DINSMORE, Christopher ,  FRADERA LLINAS, Francesc Xavier ,  KUDALE, Amit Ashokrao ,  REUTERSHAN, Michael Hale ,  THOMPSON, Christopher Francis ,  YANG, Liping ,  ALTMAN, Michael, D. ,  BOGEN, Stephane, L. ,  DOLL, Ronald, J. ,  VOSS, Matthew, E.

IPC: A61K31/519

Abstract: The present invention provides substituted pyrrolopyrimidines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. The present invention relates to novel compounds useful as Human Double Minute 2 ("HDM2") protein inhibitors, regulators or modulators, pharmaceutical compositions containing the compounds and potential methods of treatment using the compounds and compositions to potentially treat diseases such as, for example, cancer, diseases involving abnormal cell proliferation, and diseases caused by inadequate p53 levels.